1.44
-0.08 (-5.26%)
| Previous Close | 1.52 |
| Volume | 110,296 |
| Price / Sales | 6.53 |
| Price / Book | 0.570 |
| 52 Weeks Range |
| Profit Margin | -146.13% |
| Operating Margin (TTM) | -2,226.82% |
| Diluted EPS (TTM) | -1.01 |
| Quarterly Revenue Growth (YOY) | -98.80% |
| Total Debt/Equity (MRQ) | 1.80% |
| Current Ratio (MRQ) | 15.64 |
| Operating Cash Flow (TTM) | -5.60 M |
| Levered Free Cash Flow (TTM) | -3.83 M |
| Return on Assets (TTM) | -17.60% |
| Return on Equity (TTM) | -24.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Lipocine Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | -0.3 |
| AI Insight | NA |
| Weighted Average | -0.56 |
Select this tab to load the latest available analysis.
|
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP’RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.95% |
| % Held by Institutions | 9.73% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |